Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | GPR3 | P46089 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377796 | 0.77 | TNKS2 (1.00) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL29650180 | 0.77 | TNKS2 (1.00) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL450729 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL31169726 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL29624606 | 0.75 | KDM4E (1.00) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL2084671 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL1193735 | 0.75 | KDM4E (1.00) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL19751533 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6827495 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL31688848 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICAL, LLC | 2021-09-30 | — | — | US | claimed |
| EP-3377482-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | claimed |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | claimed |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | US | claimed |
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-05-28 | — | — | US | claimed |
| EP-3377482-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2018-09-26 | — | — | EP | claimed |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | claimed |
| EP-3331876-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2018-06-13 | — | — | EP | claimed |
| US-9845308-B2 | Isoindoline inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | claimed |
| WO-2017024018-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | claimed |
| CN-101293888-A | Xanthine derivative, production and use thereof as a medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-10-29 | — | — | CN | claimed |
| EP-1953162-A1 | Xanthin derivatives, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | claimed |
| CN-100408579-C | Xanthine derivatives, process for their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-08-06 | — | — | CN | claimed |
| EP-1757606-A1 | Xanthinderivatives, preparation thereof and their use as medical agents | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-02-28 | — | — | EP | claimed |
| EP-1368349-B1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-02-14 | — | — | EP | claimed |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-09-14 | — | — | US | claimed |
| CN-1492870-A | Xanthine derivatives, process for their preparation and their use as pharmaceutical compositions | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-04-28 | — | — | CN | claimed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | claimed |
| EP-1368349-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-10 | — | — | EP | claimed |
| WO-2002068420-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | RORB, RORC, RORA | CYP1A2 179/4885TNKS2 3237/4885CYP2C19 471/4885 |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | CYP1A2 341/4885TNKS2 4007/4885CYP2C19 1420/4885 |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | CYP1A2 267/4885TNKS2 4188/4885CYP2C19 811/4885 |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | CYP1A2 203/4885TNKS2 3271/4885CYP2C19 134/4885 |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | CYP1A2 341/4885TNKS2 4007/4885CYP2C19 1420/4885 |
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | CYP1A2 79/4885TNKS2 2264/4885CYP2C19 321/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | CYP1A2 828/4885TNKS2 3628/4885CYP2C19 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.